← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Nexalin Technology, Inc. (NXL) 10-Year Financial Performance & Capital Metrics

NXL • • Industrial / General
HealthcareMedical DevicesNeurological & Neurostimulation DevicesNeurostimulation & Neuromodulation
AboutNexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.Show more
  • Revenue $169K +52.3%
  • EBITDA -$8M -36.0%
  • Net Income -$8M -63.6%
  • EPS (Diluted) -0.83 -31.7%
  • Gross Margin 78.31% +2.0%
  • EBITDA Margin -4587.18% +10.7%
  • Operating Margin -4596.14% +10.6%
  • Net Margin -4508.73% -7.4%
  • ROE -221.05% -106.5%
  • ROIC -202.92% -106.7%
  • Debt/Equity -
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 9 (bottom 9%)
  • ✗Shares diluted 25.3% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-4.04%
3Y5.41%
TTM-3.18%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-56.25%

EPS CAGR

10Y-
5Y-
3Y-
TTM-4.69%

ROCE

10Y Avg-150.36%
5Y Avg-150.36%
3Y Avg-150.36%
Latest-225.34%

Peer Comparison

Neurostimulation & Neuromodulation
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
BWAYBrainsWay Ltd.452.42M23.10128.3329.04%12.73%8.92%1.44%0.09
INSPInspire Medical Systems, Inc.2.8B96.4755.1328.49%5.05%6.69%3.25%0.05
TIVCTivic Health Systems, Inc.3.11M1.23-0.06-33.67%-15.57%-134.25%
COCHEnvoy Medical, Inc.19.42M0.67-0.45-28.8%-104.75%
HSDTSolana Company128.03M3.10-0.72-19.25%-393.59%-6.89%0.01
NXLNexalin Technology, Inc.12.87M0.69-0.8352.35%-55.3%-182.01%
CVRXCVRx, Inc.143.37M5.47-2.0630.53%-92.95%-108.26%0.71
VANIVivani Medical, Inc.91.92M1.26-2.93-19.88%1.10

Profit & Loss

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+207.38K242.91K144.06K1.32M110.75K168.72K
Revenue Growth %-0.17%-0.41%8.17%-0.92%0.52%
Cost of Goods Sold+218.21K29.04K21.44K363.21K25.69K36.59K
COGS % of Revenue1.05%0.12%0.15%0.27%0.23%0.22%
Gross Profit+-10.83K213.88K122.62K958.14K85.06K132.13K
Gross Margin %-0.05%0.88%0.85%0.73%0.77%0.78%
Gross Profit Growth %-20.75%-0.43%6.81%-0.91%0.55%
Operating Expenses+1.46M3.47M6.14M2.79M5.78M7.89M
OpEx % of Revenue7.02%14.29%42.63%2.11%52.2%46.74%
Selling, General & Admin1.46M3.47M6.14M2.79M3.86M6.7M
SG&A % of Revenue7.02%14.29%42.63%2.11%34.85%39.69%
Research & Development00139K511K1.92M1.19M
R&D % of Revenue--0.96%0.39%17.35%7.06%
Other Operating Expenses00-139K-511K-189-116
Operating Income+-1.47M-3.26M-6.02M-1.83M-5.7M-7.75M
Operating Margin %-7.07%-13.41%-41.78%-1.39%-51.43%-45.96%
Operating Income Growth %--1.22%-0.85%0.7%-2.11%-0.36%
EBITDA+-1.47M-3.26M-6.02M-1.83M-5.69M-7.74M
EBITDA Margin %-7.07%-13.41%-41.77%-1.38%-51.4%-45.87%
EBITDA Growth %--1.22%-0.85%0.7%-2.11%-0.36%
D&A (Non-Cash Add-back)5354295375.72K4.25K15.11K
EBIT-1.47M-3.32M-6M-1.83M-5.7M-7.75M
Net Interest Income+0-78.68K-82.32K-59.38K-38.84K3.19K
Interest Income80.99K00003.19K
Interest Expense80.99K78.68K82.32K59.38K38.84K0
Other Income/Expense-3.56M-145.08K-59.4K135.22K1.05M147.46K
Pretax Income+-5.02M-3.4M-6.08M-1.7M-4.65M-7.61M
Pretax Margin %-24.21%-14.01%-42.19%-1.28%-41.98%-45.09%
Income Tax+000000
Effective Tax Rate %1%1%1%1%1%1%
Net Income+-5.02M-3.4M-6.08M-1.7M-4.65M-7.61M
Net Margin %-24.21%-14.01%-42.19%-1.28%-41.98%-45.09%
Net Income Growth %-0.32%-0.79%0.72%-1.74%-0.64%
Net Income (Continuing)-5.02M-3.4M-6.08M-1.7M-4.65M-7.61M
Discontinued Operations000000
Minority Interest000000
EPS (Diluted)+-0.69-0.47-0.83-0.23-0.63-0.83
EPS Growth %-0.32%-0.77%0.72%-1.74%-0.32%
EPS (Basic)-0.69-0.47-0.83-0.23-0.63-0.83
Diluted Shares Outstanding7.28M7.28M7.28M7.29M7.36M9.22M
Basic Shares Outstanding7.28M7.28M7.28M7.29M7.36M9.22M
Dividend Payout Ratio------

Balance Sheet

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+111.15K116.89K752.66K7.43M3.43M3.96M
Cash & Short-Term Investments63.43K78.44K661.78K6.99M2.95M3.48M
Cash Only63.43K78.44K661.78K162.74K580.23K574.49K
Short-Term Investments0006.83M2.37M2.91M
Accounts Receivable5.69K6.6K16.3K4.88K9.37K13.04K
Days Sales Outstanding10.019.9241.31.3530.8828.22
Inventory21.6K22.66K31.41K154.37K156.42K174.58K
Days Inventory Outstanding36.13284.77534.68155.132.22K1.74K
Other Current Assets000272.28K0293.6K
Total Non-Current Assets+1.36K1.58K1.04K6.67K202.02K261.59K
Property, Plant & Equipment1.36K1.58K1.04K6.67K4960
Fixed Asset Turnover152.82x154.13x138.66x197.99x223.28x-
Goodwill000000
Intangible Assets0000105.53K260.73K
Long-Term Investments000096K864
Other Non-Current Assets000000
Total Assets+112.51K118.46K753.7K7.43M3.63M4.22M
Asset Turnover1.84x2.05x0.19x0.18x0.03x0.04x
Asset Growth %-0.05%5.36%8.86%-0.51%0.16%
Total Current Liabilities+1.04M1.57M2.36M1.95M425.28K546.69K
Accounts Payable324.47K461.16K843.79K658.37K159.53K155.95K
Days Payables Outstanding542.745.8K14.36K661.612.27K1.56K
Short-Term Debt551.67K546.8K737.2K700K00
Deferred Revenue (Current)00130K000
Other Current Liabilities25.76K336K0336K89.33K390.75K
Current Ratio0.11x0.07x0.32x3.81x8.07x7.25x
Quick Ratio0.09x0.06x0.31x3.73x7.70x6.93x
Cash Conversion Cycle-496.6-5.5K-13.79K-505.13-13.37214.03
Total Non-Current Liabilities+250K142.24K72K4.46K00
Long-Term Debt154.82K52.3K22.92K000
Capital Lease Obligations95.18K89.93K49.09K4.46K00
Deferred Tax Liabilities000000
Other Non-Current Liabilities000000
Total Liabilities1.29M1.71M2.44M1.95M425.28K546.69K
Total Debt+826.77K726.01K850.05K755.26K4.46K0
Net Debt763.34K647.58K188.27K592.52K-575.77K-574.49K
Debt / Equity---0.14x0.00x-
Debt / EBITDA------
Net Debt / EBITDA------
Interest Coverage-18.10x-41.41x-73.11x-30.87x-146.68x-
Total Equity+-1.18M-1.59M-1.68M5.48M3.21M3.68M
Equity Growth %--0.35%-0.06%4.26%-0.41%0.15%
Book Value per Share-0.16-0.22-0.230.750.440.40
Total Shareholders' Equity-1.18M-1.59M-1.68M5.48M3.21M3.68M
Common Stock3.14K3.69K4.88K7.29K7.44K13.3K
Retained Earnings-61.21M-64.61M-70.69M-72.39M-77.04M-84.65M
Treasury Stock000000
Accumulated OCI00036.31K-405-513
Minority Interest000000

Cash Flow

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-678.34K-863.47K-1.08M-2.22M-3.84M-3.94M
Operating CF Margin %-3.27%-3.55%-7.47%-1.68%-34.63%-23.38%
Operating CF Growth %--0.27%-0.25%-1.06%-0.73%-0.03%
Net Income-5.02M-3.4M-6.08M-1.7M-4.65M-7.61M
Depreciation & Amortization5354295375354.25K15.11K
Stock-Based Compensation01.96M4.48M270.67K2.41M3.56M
Deferred Taxes066.4K-4.11M000
Other Non-Cash Items4.05M8.82K4.11M-155.02K-835.44K-34.48K
Working Capital Changes288.73K504.84K522.64K-634.07K-768.86K121.65K
Change in Receivables7.17K-909-9.7K253-4.49K-3.67K
Change in Inventory5.9K-1.06K-8.75K-142.85K-7.81K-18.16K
Change in Payables277.94K525.99K382.63K-185.43K-498.83K-3.58K
Cash from Investing+0-6480-6.79M4.45M-577.54K
Capital Expenditures0-64800-109.28K-170.31K
CapEx % of Revenue0%0%--0.99%1.01%
Acquisitions------
Investments------
Other Investing000096K0
Cash from Financing+726.05K879.13K1.66M8.51M-200K4.52M
Debt Issued (Net)------
Equity Issued (Net)------
Dividends Paid000000
Share Repurchases------
Other Financing0035.97K3.47K00
Net Change in Cash------
Free Cash Flow+-678.34K-864.12K-1.08M-2.22M-3.94M-3.94M
FCF Margin %-3.27%-3.56%-7.47%-1.68%-35.62%-23.38%
FCF Growth %--0.27%-0.25%-1.06%-0.78%0%
FCF per Share-0.09-0.12-0.15-0.30-0.54-0.43
FCF Conversion (FCF/Net Income)0.14x0.25x0.18x1.31x0.83x0.52x
Interest Paid000000
Taxes Paid000000

Key Ratios

Metric201920202021202220232024
Return on Equity (ROE)----89.44%-107.05%-221.05%
Return on Invested Capital (ROIC)----60.07%-98.19%-202.92%
Gross Margin-5.22%88.05%85.12%72.51%76.81%78.31%
Net Margin-2421.22%-1401.11%-4218.93%-128.49%-4197.56%-4508.73%
Debt / Equity---0.14x0.00x-
Interest Coverage-18.10x-41.41x-73.11x-30.87x-146.68x-
FCF Conversion0.14x0.25x0.18x1.31x0.83x0.52x
Revenue Growth-17.13%-40.69%817.2%-91.62%52.35%

Revenue by Segment

202220232024
Licensing Fee79.19K82.08K69.5K
Licensing Fee Growth-3.65%-15.33%
Device Sales1.16M-55.5K
Device Sales Growth---
Equipment26.78K27.3K37.83K
Equipment Growth-1.95%38.56%
Other26.41K1.37K5.89K
Other Growth--94.82%330.53%

Revenue by Geography

202220232024
CHINA1.21M3.61K85.25K
CHINA Growth--99.70%2258.83%
UNITED STATES113.54K107.13K83.47K
UNITED STATES Growth--5.64%-22.09%

Frequently Asked Questions

Growth & Financials

Nexalin Technology, Inc. (NXL) reported $0.2M in revenue for fiscal year 2024. This represents a 24% decrease from $0.2M in 2019.

Nexalin Technology, Inc. (NXL) grew revenue by 52.3% over the past year. This is strong growth.

Nexalin Technology, Inc. (NXL) reported a net loss of $8.7M for fiscal year 2024.

Dividend & Returns

Nexalin Technology, Inc. (NXL) has a return on equity (ROE) of -221.1%. Negative ROE indicates the company is unprofitable.

Nexalin Technology, Inc. (NXL) had negative free cash flow of $5.0M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.